A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide
M. Hodges, E. Castelloe, A. Chen, R. Geary, J. Karras, R. Larouche, D. Shapiro, B. Yeung, R. Yu, S. Gregory (San Diego, Carslbad, United States Of America; Montréal, Canada)
Source: Annual Congress 2009 - New drugs for airways disease
Session: New drugs for airways disease
Session type: Oral Presentation
Number: 1800
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hodges, E. Castelloe, A. Chen, R. Geary, J. Karras, R. Larouche, D. Shapiro, B. Yeung, R. Yu, S. Gregory (San Diego, Carslbad, United States Of America; Montréal, Canada). A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide. Eur Respir J 2009; 34: Suppl. 53, 1800
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
An open-label trial to investigate the dose delivery and tolerability of inhaled dry powder mannitol (IDPM) using low output and high output OrbitalÔ inhalers across defined flow rates in healthy volunteers Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β2 adrenoreceptor agonist, PF-00610355 in asthmatic patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
A randomised, 4-way crossover study to examine the lung pharmacodynamic effects of single inhaled doses of tiotropium (18 μg), salmeterol (50 μg), tiotropium (18 μg) and salmeterol (50 μg) and placebo using whole body plethysmography in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010